Acadia Q1 NUPLAZID sales $115.5M (+8% YoY); net loss widens to $113.1M on $60M Stoke payment

ACADIA PHARMACEUTICALS INC

2022-FY EPS reported -$0.70 revenue$115,468,000

Q1 NUPLAZID net sales $115.5M (+8% vs $106.6M Q1 2021); net loss $113.1M ($0.70/sh) vs $66.4M loss in prior year.
R&D expense surged to $128.9M from $57.0M, driven by $60M upfront payment to Stoke Therapeutics under license deal.
Cash and investments $446.0M at March 31, 2022, down from $520.7M at Dec 31, 2021.
FY2022 NUPLAZID net sales guidance reiterated at $510-$560M; FDA AdComm for pimavanserin in ADP set for June 17, 2022.
Trofinetide NDA for Rett syndrome on track for mid-2022; Parag Meswani and Holly Valdiviez joined as senior commercial leads.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.